Analysis of the mechanism of action and efficacy of cemiplimab

Cemiplimab (Cemiplimab) is a fully human monoclonal antibody targeting programmed death receptor-1 (PD-1). Its main mechanism of action is to block the immunosuppressive signal between tumor cells and T cells. PD-1 is a negative regulatory molecule on the surface of T cells. When it binds to the ligand PD-L1, it inhibits T cell proliferation and effector functions, thereby reducing the body's immune response to tumor cells. Cimepilimab binds to the PD-1 receptor, making it unable to bind to PD-L1 or PD-L2, thereby releasing the suppressed state of T cells, restoring the killing function of T cells, and enhancing the body's anti-tumor immunity.

In terms of efficacy, cimepilimab has shown anti-tumor activity in a variety of solid tumors. In clinical applications for advanced cutaneous squamous cell carcinoma, cimepilimab can delay tumor progression, reduce lesion volume, and achieve long-term remission in some patients by continuously activating T cells. The persistence of its efficacy is closely related to the continuous blockade of the PD-1 pathway, which is why clinically it is recommended to use the medication according to a fixed course of treatment.

In addition, cimepilimab has also shown certain single-agent efficacy in patients with non-small cell lung cancer, especially in patients with positive PD-L1 expression. By removing the immunosuppressive environment, T cells can more effectively recognize and eliminate tumor cells, thereby improving patient survival prognosis. The combination of chemotherapy or other immune checkpoint inhibitors has also shown a trend of synergy in some clinical trials.

The efficacy of cimepilimab is not only reflected in tumor shrinkage or response rate, but also includes improving patients' quality of life and prolonging progression-free survival. Due to its clear targeting, it is usually well tolerated and has lower systemic side effects than traditional chemotherapy, allowing patients to maintain a relatively good life during long-term treatment.

Reference materials:https://www.libtayohcp.com/